Last reviewed · How we verify
NCT03930212: Prothreat
Progesterone Supplementation in Threatened Abortion
Phase 4 trial testing Progesterone in Threatened Abortion in 190 participants. Completed in 31 December 2018.
31 December 2018
Quick facts
| Lead sponsor | Tanta University |
|---|---|
| Phase | Phase 4 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | treatment |
| Enrollment | 190 |
| Start date | 1 January 2018 |
| Primary completion | 31 December 2018 |
| Estimated completion | 31 December 2018 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Progesterone (Progesterone plus HCG) — full drug profile →
- Placebos — full drug profile →
Conditions studied
- Threatened Abortion — all drugs for Threatened Abortion →
- Progesterone Resistance — all drugs for Progesterone Resistance →
Sponsor
Tanta University
Who can join
Adults 20 to 40, female only, with Threatened Abortion or Progesterone Resistance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To decide whether progesterone supplementation in threatened abortion is a sound practice.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Progestogens for preventing miscarriage: a network meta-analysis.
Devall AJ, Papadopoulou A, Podesek M, Haas DM, et al · · 2021 · cited 55× · PMID 33872382 · DOI 10.1002/14651858.cd013792.pub2
Verify or expand the search:
- PubMed search for NCT03930212
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Progesterone
Trials testing the same drug.
- NCT07372495 — Cerclage Plus Progesterone vs Progesterone Alone in Twin Short Cervix · NA · not yet recruiting
- NCT06631547 — Effect of Progesterone Administration on Severely Head Injured Patients · Phase 1 · not yet recruiting
- NCT07162961 — Nintedanib for Improving Reproductive Outcomes in Adenomyosis · Phase 3 · not yet recruiting
- NCT06851754 — Hormone Replacement Therapy in Adolescents With Premature Ovarian Insufficiency · Phase 3 · recruiting
- NCT06928844 — Role of Low Dose Injectable Progesterone in Triggering Ovulation · NA · recruiting
Other Tanta University trials
Trials by the same sponsor.
- NCT07398651 — Apremilast and Adalimumab in Psoriatic Arthritis Patients · NA · not yet recruiting
- NCT06966856 — This Randomized, Clinical Trial Evaluates the Efficacy of Oral Versus Sublingual Vitamin B12 Supplementation in Correcti · Phase 3 · not yet recruiting
- NCT07334197 — Effect of Melatonin on Left Ventricular Reverse Remodeling and Inflammation in Peripartum Cardiomyopathy · NA · not yet recruiting
- NCT07498998 — Glucocorticoid, Ozone and 5% Dextrose Local Injection for Pain Relief in Carpal Tunnel Syndrome · NA · not yet recruiting
- NCT07114250 — Comparative Study Between Spinal Anesthesia Versus General Anesthesia in Supine Percutaneous Nephrolithotomy Operation · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03930212 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tanta University
- Last refreshed: 18 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03930212.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing